1992Scandinavian Journal of RheumatologyRequires access

Efficacy of Arthrotec® in the Treatment of Rheumatoid Arthritis

J. R. Haniwquin

Open publisher page 6 citations

Abstract

In a double-blind study, 346 patients with active rheumatoid arthritis were randomly assigned to receive Arthrotec®, a combination of 50 mg of diclofenac and 200 *g of misoprostol, or 50 mg of diclofenac; the drugs were given two or three times daily for 12 weeks. At weeks 4, 8. and 12 of treatment, no clinically significant differences between the two treatment groups were noted on measum of joint tenderness, pain, and swelling or on physicians' and patients' assessments of disease severity.

About this research paper

What this paper is about

In a double-blind study, 346 patients with active rheumatoid arthritis were randomly assigned to receive Arthrotec®, a combination of 50 mg of diclofenac and 200 *g of misoprostol, or 50 mg of diclofenac; the drugs were given two or three times daily for 12 weeks. At weeks 4, 8. and 12 of treatment, no clinically significant differences between the two treatment groups were noted on measum of joint tenderness, pain, and swelling or on physicians' and patients' assessments of disease severity.

Why it matters

OpenAlex reports 6 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

In a double-blind study, 346 patients with active rheumatoid arthritis were randomly assigned to receive Arthrotec®, a combination of 50 mg of diclofenac and 200 *g of misoprostol, or 50 mg of diclofenac; the drugs were given two or three times daily for 12 weeks. At weeks 4, 8. and 12 of treatment, no clinically significant differences between the two treatment groups were noted on measum of joint tenderness, pain, and swelling or on physicians' and patients' assessments of disease severity.

Key concepts: Medicine, Diclofenac, Rheumatoid arthritis, Misoprostol, Tenderness, Internal medicine, Arthritis, Joint pain

Related papers

Back to paper searchBrowse research topicsOriginal source
Efficacy of Arthrotec® in the Treatment of Rheumatoid Arthritis — Research Paper | ScholarLens